PARADIGM

What have been the major advances in CRC care in the past 25 years? 5:02
What have been the major advances in CRC care in the past 25 years?
Alberto Sobrero • 30 Jun 2023
Is front-line anti-EFGR therapy essential in RAS-WT mCRC? 5:05
Is front-line anti-EFGR therapy essential in RAS-WT mCRC?
Ardaman Shergill • 26 Jan 2023
DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC 3:01
DEEPER: m-FOLFOXIRI and cetuximab versus bevacizumab in mCRC
Yu Sunakawa • 20 Jan 2023
PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC 2:42
PARADIGM: panitumumab versus bevacizumab in RAS-wt mCRC
Kohei Shitara • 19 Jan 2023
Targeting less common mutations in colorectal cancer 3:08
Targeting less common mutations in colorectal cancer
Sebastian Stintzing • 10 Sep 2022
PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC 2:43
PARADIGM: Panitumumab plus mFOLFOX6 in RAS wt mCRC
Chiara Cremolini • 4 Jun 2022
How will the PARADIGM trial change the mCRC treatment landscape? 1:05
How will the PARADIGM trial change the mCRC treatment landscape?
Chiara Cremolini • 4 Jun 2022
Anti-EGFR therapy for RAS wild-type left-sided colorectal cancer 2:10
Anti-EGFR therapy for RAS wild-type left-sided colorectal cancer
Richard D. Kim • 6 Jun 2022
Exciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancer 1:02
Exciting updates from ASCO 2022 in the anti-EGFR rechallenge space for colorectal cancer
Christine Megerdichian Parseghian • 5 Jun 2022
Panitumumab + mFOLOFOX6 as the new standard of care for RAS WT metastatic colorectal cancer 0:33
Panitumumab + mFOLOFOX6 as the new standard of care for RAS WT metastatic colorectal cancer
Takayuki Yoshino • 5 Jun 2022
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC 1:28
PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC
Takayuki Yoshino • 5 Jun 2022
The content of VJOncology is intended for healthcare professionals